NCT03000647 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L
Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg. 1999 Mar;99(1):61-4.
Gilpin SA, Gilpin CJ, Dixon JS, Gosling JA, Kirby RS
The effect of age on the autonomic innervation of the urinary bladder. Br J Urol. 1986 Aug;58(4):378-81.
Litwiller SE, Frohman EM, Zimmern PE
Multiple sclerosis and the urologist. J Urol. 1999 Mar;161(3):743-57. Review. Erratum in: J Urol 1999 Jul;162(1):172.
Lúcio AC, Campos RM, Perissinotto MC, Miyaoka R, Damasceno BP, D'ancona CA
Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. Neurourol Urodyn. 2010 Nov;29(8):1410-3. doi: 10.1002/nau.20941.
Quarto G, Autorino R, Gallo A, De Sio M, D'Armiento M, Perdonà S, Damiano R
Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Feb;18(2):189-94. Epub 2006 May 13.

Assessment of the Effectiveness of Guided by a Physiotherapist Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence (UI) in Patients With Relapsing-Remitting (RR) Multiple Sclerosis

Details for clinical trial NCT03000647

Clinical trial NCT03000647 - References